Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2- Overexpressing Metastatic Breast Cancer

E-ISSN： 1873-5592|14|8|889-898

ISSN： 1389-4501

Source： Current Drug Targets, Vol.14, Iss.8, 2013-07, pp. : 889-898

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

Current Cancer Drug Targets, Vol. 15, Iss. 8, 2015-01 ,pp. : 665-683

Bentham Science Publishers

Access to resources Recommend Favorite

Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 148-162

Bentham Science Publishers

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2

By McKeage K. Perry C.M.

Drugs, Vol. 62, Iss. 1, 2002-01 ,pp. : 209-243

Adis International

Access to resources Recommend Favorite

Lapatinib: A Review of its Use in the Treatment of HER2-Overexpressing, Trastuzumab-Refractory, Advanced or Metastatic Breast Cancer

By Frampton James E.

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2125-2148

Adis International

Access to resources Recommend Favorite

First-line therapy with trastuzumab plus paclitaxel and carboplatin may be active in patients with HER-2 over-expressing metastatic breast cancer

Inpharma, Vol. 1, Iss. 1441, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite